179 related articles for article (PubMed ID: 20065058)
1. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
Lauderdale TL; Shiau YR; Lai JF; Chen HC; King CH
Antimicrob Agents Chemother; 2010 Mar; 54(3):1338-42. PubMed ID: 20065058
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
3. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC
J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
Adam HJ; Laing NM; King CR; Lulashnyk B; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2009 Nov; 53(11):4915-20. PubMed ID: 19738018
[TBL] [Abstract][Full Text] [Related]
5. Nemonoxacin has potent activity against gram-positive, but not gram-negative clinical isolates.
Li ZX; Liu YN; Wang R; Li AM
Clin Ter; 2015; 166(6):e374-80. PubMed ID: 26794819
[TBL] [Abstract][Full Text] [Related]
6. Selected Mutations by Nemonoxacin and Fluoroquinolone Exposure Among Relevant Gram-Positive Bacterial Strains in Taiwan.
Yang JJ; Cheng A; Tai HM; Chang LW; Hsu MC; Sheng WH
Microb Drug Resist; 2020 Feb; 26(2):110-117. PubMed ID: 31478786
[TBL] [Abstract][Full Text] [Related]
7. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
Nilius AM; Shen LL; Hensey-Rudloff D; Almer LS; Beyer JM; Balli DJ; Cai Y; Flamm RK
Antimicrob Agents Chemother; 2003 Oct; 47(10):3260-9. PubMed ID: 14506039
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
Yang JC; Lee PI; Hsueh PR
Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1369-75. PubMed ID: 20658256
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.
Wickman PA; Black JA; Moland ES; Thomson KS
Antimicrob Agents Chemother; 2006 Jun; 50(6):2255-7. PubMed ID: 16723599
[TBL] [Abstract][Full Text] [Related]
10. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
Soussy CJ; Nguyen J; Goldstein F; Dabernat H; Andremont A; Leclercq R; Drugeon H; Cavallo P; Chardon H; Etienne J; Rio Y; Courvalin P
Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
Hardy D; Amsterdam D; Mandell LA; Rotstein C
Antimicrob Agents Chemother; 2000 Mar; 44(3):802-5. PubMed ID: 10681365
[TBL] [Abstract][Full Text] [Related]
12. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
14. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients.
Rolston KV; Frisbee-Hume S; LeBlanc B; Streeter H; Ho DH
Diagn Microbiol Infect Dis; 2003 Oct; 47(2):441-9. PubMed ID: 14522520
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial activities of nemonoxacin against clinical isolates of Staphylococcus aureus: an in vitro comparison with three fluoroquinolones.
Li Z; Liu Y; Wang R; Li A
World J Microbiol Biotechnol; 2014 Nov; 30(11):2927-32. PubMed ID: 25129332
[TBL] [Abstract][Full Text] [Related]
16. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin.
Aktaş Z; Gönüllü N; Salcioğlu M; Bal C; Anğ O
Int J Antimicrob Agents; 2002 Sep; 20(3):196-200. PubMed ID: 12385698
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of BAY 12-8039, a new fluoroquinolone.
Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
19. In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
Hong SG; Moland ES; Wickman PA; Black JA; Hossain A; Hanson ND; Thomson KS
Antimicrob Agents Chemother; 2007 Apr; 51(4):1512-4. PubMed ID: 17220419
[TBL] [Abstract][Full Text] [Related]
20. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
Hidalgo M; Reyes J; Cárdenas AM; Díaz L; Rincón S; Vanegas N; Díaz PL; Castañeda E; Arias CA
Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]